AnnJi Pharmaceutical initiates Phase 3 testing for AJ201, the only clinical-stage oral therapy currently in development for spinal and bulbar muscular atrophy (SBMA).
AnnJi Pharmaceutical is currently advancing AJ201 (Rosolutamid) into a pivotal Phase 3 clinical trial, marking it as the only known investigational therapy globally for spinal and bulbar muscular atrophy (SBMA). The drug functions as an orally administered small molecule designed to target multiple underlying disease mechanisms of this condition.
AJ201, also known as Rosolutamid, is an orally administered small molecule drug currently in Phase 3 clinical development for treating SBMA.
It targets spinal and bulbar muscular atrophy (SBMA) by addressing multiple disease mechanisms.
AnnJi Pharmaceutical has moved its lead candidate, AJ201 (Rosolutamid), into a pivotal Phase 3 clinical trial. The oral small-molecule therapy targets the underlying mechanisms of spinal and bulbar muscular atrophy (SBMA), marking a significant milestone in the development of the world's only known late-stage treatment for the condition.
AJ201 is currently the only known therapeutic candidate in Phase 3 clinical development for spinal and bulbar muscular atrophy (SBMA), positioning it as a potential first-in-class treatment.